Mankind Pharma has announced the acquisition of Bharat Serums and Vaccines Limited (BSV) from Advent International to expands its high entry barriers portfolio and gain leadership in women’s health.
Mankind Pharma (http://www.mankindpharma.com/) has acquired 100 per cent stake (73,086 equity shares) in Bharat Serums and Vaccines Limited (BSV) from Advent International, one of the largest and most experienced global private equity firms, at an enterprise value of Rs. 13,630 Crores approximately. At the board meeting held on July 25, The Board of Directors of the Company approved the acquisition of BSV Limited.
This acquisition will help Mankind Pharma to expand its high entry barriers and to gain leadership in women’s health, fertility, critical care and Immunoglobulin segment. The acquisition will also establish Mankind Pharma as market leader in Indian Women’s health & fertility segment.
Incorporated in November 1993, Bharat Serums and Vaccines Limited is a leading branded specialty pharma platform in Women’s health and critical care with huge opportunity in both India and international markets.
BSV has achieved consolidated turnover of Rs. 1,245.29 Crores IN FY 2022, Rs. 1,435.44 Crores in FY 2023 and Rs. 1,723.47 Crores in FY 2024. BSV has an Paid up capital of Rs. 351.72 Crores as on date.
BSV is engaged in the business of research, development, licensing,
manufacturing, importing, exporting, marketing and distribution of: (a) branded
pharmaceutical formulations, active pharmaceutical ingredients (API); (b) biotech
and biological formulations, and / or API; (c) food and health supplements; (d)
medical devices; and (e) ayurvedic medicines; in each case, in the therapeutic
areas such as gynaecology, in-vitro fertilisation (IVF), critical care and/or
emergency medicines for human use.
BSV has 6 (six) subsidiaries in India, Philippines, Germany, USA and Malaysia.
Further, BSV has business operations in more than 50 countries.
Also Read –
